ReviewClinical rheumatology2015
Early systemic sclerosis-opportunities for treatment.
Review in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Ischemia-modified albumin in rheumatic diseases: A systematic review and meta-analysis.Immunity, inflammation and disease · 2024Pooled it
- A systematic review and meta-analysis of neopterin in rheumatic diseases.Frontiers in immunology · 2023Pooled it
- Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.Rheumatology international · 2020Trial
- Chimeric antigen receptor macrophage (CAR-M) immunotherapy in autoimmune inflammatory rheumatic diseases.Clinical rheumatology · 2026Review
- Regulatory T cells as a potential treatment for autoimmune inflammatory rheumatic and musculoskeletal diseases.Clinical rheumatology · 2026Review
- Exosome immunotherapy in inflammatory rheumatic and musculoskeletal diseases: a novel immunotherapeutic frontier.Clinical rheumatology · 2026Review
- CAR-T cells in systemic sclerosis.Clinical rheumatology · 2026Review
- Development and validation of a new diagnostic prediction model of ENHO and NOX4 for early diagnosis of systemic sclerosis.Frontiers in immunology · 2024Article
- Higher gamma-glutamyl transferase levels are associated with an increased risk of incident systemic sclerosis: a nationwide population-based study.Scientific reports · 2023Article
- Hypoxia-Inducible Factor-1α (HIF-1α) as a Biomarker for Changes in Microcirculation in Individuals with Systemic Sclerosis.Dermatology and therapy · 2023Article
- Association Between Lipid Profile and Risk of Incident Systemic Sclerosis: A Nationwide Population-Based Study.Clinical epidemiology · 2023Article
- Nailfold Videocapillaroscopy is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients.Diagnostics (Basel, Switzerland) · 2020Article
- Targeting very early systemic sclerosis: a case-based review.Rheumatology international · 2019Review
- Long-term effects of immunosuppressive therapy on lung function in scleroderma patients.Clinical rheumatology · 2018Article
- Immunotherapy of systemic sclerosis.Human vaccines & immunotherapeutics · 2018Article
- Adenosine AThe American journal of pathology · 2017Article
- Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis.Current opinion in rheumatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is characterized by microvasculopathy (Raynaud's phenomenon and fibrointimal proliferation), presence of autoantibodies and collagen deposition in skin (scleroderma) and internal organs. Microvasculopathy, detected by nailfold capillaroscopy, and disease-specific autoantibodies (anti-topoisomerase I, anti-centromere, anti-RNA polymerase III antibodies) usually appear earlier, even years before scleroderma. At that stage of the disease, immune activation with T cells and B cells promote fibrosis. Diagnosis of SSc has been relied on scleroderma, and by this time, internal organs may have developed fibrosis, a lethal feature with no available treatment. The new EULAR/ACR 2013 criteria for the classification of SSc will help identify SSc patients before fibrosis of internal organs. The early diagnosis of SSc, before the development of fibrosis in internal organs, will allow the introduction of immunosuppressive medications in these patients in a controlled setting (randomized trials). It is anticipated that this approach will change the hitherto grim prognosis of SSc for the better.
Indexed as
Identifiers
25711876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.